Drug Recall: PEPTIME Energy Caffeine Tablets cGMP Violations
Ultra Seal Corporation is recalling PEPTIME Energy 300mg caffeine tablets nationwide due to current Good Manufacturing Practice (cGMP) deviations. The recall affects 131,112 packets and 8,064 bottles distributed across the United States.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for manufacturing deviations. The source text does not report any illnesses, injuries, or hospitalizations, and the recall is based on process compliance issues rather than documented harm. Per the rubric, Class II recalls without reported illness typically fall in the Moderate range.
Plain-English summary
Ultra Seal Corporation is voluntarily recalling PEPTIME Energy caffeine tablets (300mg) packaged in both 6-count packets (Lot #19E030) and 100-count bottles (Lot #19E031) due to current Good Manufacturing Practice (cGMP) deviations. The product is marketed by DMD Pharmaceuticals, a division of Dickery Consumer Products, Inc., based in Noblesville, Indiana.
Approximately 131,112 packets and 8,064 bottles have been distributed nationwide within the United States. The FDA classified this as a Class II recall.
Consumers who have purchased PEPTIME Energy tablets from the affected lots should stop use and consult their healthcare provider with questions. The recalling firm initiated this recall on January 24, 2022, and the recall was terminated on October 16, 2023.
The recalled product
- Product
- PEPTIME Energy (caffeine 300mg) tablets, packaged in a) 6 count packets and b) 100-count bottles, Marketed by: DMD Pharmaceuticals, A Division of Dickery Consumer Products, Inc., Noblesville, IN 46060.
- Manufacturer
- Ultra Seal Corporation
- Hazard
- cGMP-violation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: a)19E030
- b)19E031
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27